Sugi Predict

Sugi Predict / Compounds / SCHEMBL1934571

SCHEMBL1934571

SCHEMBL1934571

O=C(O)C1CCC(N(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ YTHDC1 Q96MU7 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TAS2R14 Q9NYV8 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ POLB P06746 1/20 0.45
▸ OPRM1 P35372 2/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ACKR3 P25106 1/20 0.43
▸ DPP8 Q6V1X1 1/20 0.43
▸ DPP7 Q9UHL4 1/20 0.43
▸ CCR5 P51681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282446 1.00 MEN1 (0.54) MEN1KMT2AYTHDC1L3MBTL1TAS2R14
Hydrochloric Acid SCHEMBL1543195 0.98 MEN1 (0.53) MEN1KMT2AYTHDC1L3MBTL1TAS2R14
Hydrochloric Acid SCHEMBL1543198 0.98 MEN1 (0.53) MEN1KMT2AYTHDC1L3MBTL1TAS2R14
SCHEMBL1536135 0.90 MEN1 (0.51) MEN1KMT2AYTHDC1L3MBTL1TAS2R14
SCHEMBL21222573 0.90 MEN1 (0.54) MEN1KMT2AYTHDC1ALDH1A1GAA
SCHEMBL1543260 0.90 MEN1 (0.54) MEN1KMT2AYTHDC1ALDH1A1GAA
SCHEMBL16216060 0.87 MEN1 (0.51) MEN1KMT2AYTHDC1ALDH1A1OPRM1
SCHEMBL1933310 0.87 MEN1 (0.51) MEN1KMT2AYTHDC1ALDH1A1OPRM1
SCHEMBL27889749 0.87 MEN1 (0.51) MEN1KMT2AYTHDC1ALDH1A1GAA
SCHEMBL25568594 0.87 MEN1 (0.51) MEN1KMT2AYTHDC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2021-08-05 — — US claimed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 — — US disclosed
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 — — CN disclosed
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2025-01-16 — — US disclosed
EP-4433476-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS Merck Sharp & Dohme LLC (US) 2024-09-25 — — EP disclosed
CN-114423753-B Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2024-09-17 — — CN disclosed
CN-118265711-A Chromanamidine monocyclic lactam antibiotics 默沙东有限责任公司 2024-06-28 — — CN disclosed
US-11932637-B2 Chromane amidine monobactam compounds for the treatment of bacterial infections MERCK SHARP & DOHME LLC (US) 2024-03-19 — — US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 — — US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 — — US disclosed
WO-2013013188-A1 HETEROCYCLIC PROTEIN KINASE INHIBITORS TOLERO PHARMACEUTICALS, INC. (US) 2013-01-24 — — WO disclosed
EP-2506716-A1 NOVEL TRICYCLIC COMPOUNDS Abbott Laboratories (US) 2012-10-10 — — EP disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 — — US disclosed
WO-2011123493-A1 SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-06 — — WO disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
EP-2010186-A1 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Signal Pharmaceuticals LLC (US) 2009-01-07 — — EP disclosed
WO-2007127382-A1 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM MEN1 77/4885KMT2A 2833/4885YTHDC1 1630/4885
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS PAM, ACMSD, MGAM2 MEN1 270/4885KMT2A 1492/4885YTHDC1 1900/4885
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 MEN1 1760/4885KMT2A 1046/4885YTHDC1 2935/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B MEN1 4829/4885KMT2A 2514/4885YTHDC1 1951/4885
US-11932637-B2 Chromane amidine monobactam compounds for the treatment of bacterial infections MGAM, MGAM2, ELANE MEN1 110/4885KMT2A 2333/4885YTHDC1 2804/4885
US-20110311474-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 MEN1 267/4885KMT2A 3881/4885YTHDC1 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.